|
Transplant anti-rejection drugs and risk of melanoma |
 |
 |
|
UPI: Organ transplant patients are twice as likely as people without transplants to develop melanoma and 3 times as likely to die from it, according to a new study. Researchers found that patients were more likely to develop melanoma within the first 4 years of taking immunosuppressive drugs meant to keep their bodies from rejecting transplanted organs. Previously, scientists thought the potential for the drugs to influence cancer development would come after many years of taking the drugs.
|
|
State nod for Siddhivinayak temple trust's donation of dialysis units - Times of India |
|
|
|
MUMBAI: The Devendra Fadnavis-led BJP government on Thursday approved a proposal submitted by the Shri Siddhivinayak Ganpati temple trust's Rs 7.5-crore proposal for setting up 102 dialysis units and water purification plants in 24 districts across the state. The law and judiciary department has promulgated a four-page order to provide for the dialysis units and water purification plants.
The TOI report on Tuesday, "Govt sat on temple donation of dialysis machines", had highlighted that a crucial proposal had been gathering dust in the office of the minister of state for law and judiciary Ranjeet Patil, an orthopaedic surgeon by profession, since April 9, owing to red tape and procedural wrangles in the report.
A bureaucrat had told TOI that the proposal was not cleared as the temple trust had declined to clear another plan for setting up an MRI unit in a private organization. "The proposal was not acceptable since as per the legal provisions, the trust can consider proposals submitted by government and semi-government organizations but not private ones."
The bureaucrat said that on April 1, 2014, the director of health services had submitted a comprehensive proposal to the trust for providing final aid to set up dialysis units, and after scrutiny, it was approved and submitted to the law and judiciary department on April 9, 2015.
Last week, while interacting with doctors in Pune, Fadnavis had declared that his government will rope in leading temple trusts for strengthening health care across the state.
A former dean expressed concern over the deterioration of state-run medical colleges. "In the last two decades, we have neither been able to set up a new department in any of the 14 state-run medical colleges nor has there been adequate research on new trends in the medical field."
|
|
|
Societe Generale Downgrades Fresenius Medical Care to Hold - Money Flow Index |
|
|
|
Brokerage firm Societe Generale Downgrades its rating on Fresenius Medical Care(NYSE:FMS). The shares have been rated Hold. Previously, the analysts had a Buy rating on the counter. The rating by Societe Generale was issued on Aug 13, 2015.
Fresenius Medical Care Corporation (NYSE:FMS): 5 analysts have set the short term price target of Fresenius Medical Care Corporation (NYSE:FMS) at $43.61. The standard deviation of short term price target has been estimated at $5.04, implying that the actual price may fluctuate by this value. The higher and the lower price estimates are $ 50 and $39 respectively. Institutional Investors own 2% of Company shares. During last 3 month period, 1.24% of total institutional ownership has changed in the company shares. The company shares have rallied 19.84% from its 1 Year high price. On Jun 4, 2015, the shares registered one year high at $44.34 and the one year low was seen on Oct 16, 2014. The 50-Day Moving Average price is $42.47 and the 200 Day Moving Average price is recorded at $41.34. Fresenius Medical Care Corporation (NYSE:FMS) : On Monday heightened volatility was witnessed in Fresenius Medical Care Corporation (NYSE:FMS) which led to swings in the share price. The shares opened for trading at $41.4 and hit $41.78 on the upside , eventually ending the session at $41.77, with a gain of 0.51% or 0.21 points. The heightened volatility saw the trading volume jump to 1,101,268 shares. The 52-week high of the share price is $44.34 and the company has a market cap of $26,081 million. The 52-week low of the share price is at $32.4 . Fresenius Medical Care AG & Co KGaA is a Germany-based kidney dialysis company that operates in the fields of dialysis care and dialysis products for the treatment of end-stage renal disease (ESRD). Its dialysis business is vertically integrated and offers products and services for the entire dialysis value chain, providing dialysis treatment at dialysis clinics it owns or operates and supplying these clinics with a range of products. The Company offers two types of dialysis treatment: Hemodialysis (HD), where the machine controls the blood from the patient through a special filter, the dialyzer, and Peritoneal Dialysis (PD), where the patient’s peritoneum is used as a dialyzing membrane. Its dialysis product portfolio includes chronic hemodialysis, home dialysis, renal pharmaceuticals, acute therapy, liver support, therapeutic apheresis, therapy support and water technology, among others. In addition, the Company sells dialysis products to other dialysis service providers.
|
|
Necrotizing Enterocolitis in a mouse model leads to widespread renal ... - Nature.com |
|
|
BACKGROUND:
Necrotizing enterocolitis (NEC) is a devastating condition affecting premature infants and leads to high mortality and chronic morbidity. Severe form of NEC is associated with acute renal failure, fluid imbalance, hyponatremia and acidosis. We investigated the effect of NEC on tight junction (TJ) proteins in kidneys using a NEC mouse model to investigate the basis for the observed renal dysfunction.
METHODS:
NEC was induced in C57BL/6 mice by formula feeding and subjecting them to periods of hypoxia and cold stress. NEC was confirmed by gross and histological examination. We studied various markers of inflammation in kidneys and investigated changes in expression of several TJ proteins and AQP2 using immunofluorecent staining and Western blotting.
RESULTS:
We found markedly increased expression of NF?B, TGF? and ERK1/2 along with claudin-1, -2, -3, -4, -8 and AQP-2 in NEC kidneys. The membrane localization of claudin-2 was altered in the NEC kidneys and its immunostaining signal at TJ was disrupted.
CONCLUSION:
NEC led to a severe inflammatory response not only in the gut but also the kidneys. NEC increased expression of several TJ proteins and caused disruption of claudin-2 in renal tubules. These observed changes can help explain some of the clinical findings observed in NEC.
|
|
Log in to explore the world's most comprehensive database of dialysis centres for free! 
Professional dialysis recruitment
